Combination Therapy with Rituximab, Tofacitinib and Pirfenidone in a Patient with Rapid Progressive Interstitial Lung Disease (RP-ILD) Due to MDA5 Antibody-Associated Dermatomyositis: A Case Report
Yen, T.-H.; Tseng, C.-W.; Wang, K.-L.; Fu, P.-K. Combination Therapy with Rituximab, Tofacitinib and Pirfenidone in a Patient with Rapid Progressive Interstitial Lung Disease (RP-ILD) Due to MDA5 Antibody-Associated Dermatomyositis: A Case Report. Medicina 2021, 57, 1358. https://doi.org/10.3390/medicina57121358
Yen T-H, Tseng C-W, Wang K-L, Fu P-K. Combination Therapy with Rituximab, Tofacitinib and Pirfenidone in a Patient with Rapid Progressive Interstitial Lung Disease (RP-ILD) Due to MDA5 Antibody-Associated Dermatomyositis: A Case Report. Medicina. 2021; 57(12):1358. https://doi.org/10.3390/medicina57121358
Chicago/Turabian StyleYen, Tsai-Hung, Chih-Wei Tseng, Kao-Lun Wang, and Pin-Kuei Fu. 2021. "Combination Therapy with Rituximab, Tofacitinib and Pirfenidone in a Patient with Rapid Progressive Interstitial Lung Disease (RP-ILD) Due to MDA5 Antibody-Associated Dermatomyositis: A Case Report" Medicina 57, no. 12: 1358. https://doi.org/10.3390/medicina57121358